This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
10 - 12 June, 2025
Congress CenterBasel Switzerland
10 - 12 June, 2025
Congress Center,
Basel Switzerland

Coming to London: 2024 Agenda Topics Preliminary Agenda Just Launched!

Brand New Topic Streams On The Latest In Antibody Science

Each year Antibody Engineering & Therapeutics Europe's scientific agenda brings you 100+ leading antibody and protein engineering scientists diving into the critical updates within the industry.

Take a look below to see the confirmed session themes and chairs for 2024.

Fc Engineering

Session Co-Chairs:
Sally Ward, Ph.D., Professor and Director, University of Southampton,United Kingdom

Robert de Jong, Ph.D., Director Antibody Research & Technology, Genmab, The Netherlands

Novel Approaches to Antibody Discovery

Session Chair:
James A. Ernst, Ph.D., Vice President, Head of Development Sciences, Xencor

Challenges in Discovery & Optimization of Multispecific Antibodies

Session Chair:
Rene Hoet, Ph.D., Chief Innovations Officer, FairJourney Biologics, Portugal

Agonist Antibodies

Session Chair:
Stephen Beers, Ph.D., Professor of Immunology and Immunotherapy, Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, United Kingdom

Conditionally Active Biotherapeutics

Session Chair:
Benjamí Oller-Salvia, Ph.D., Assistant Professor at IQS Barcelona, Ramon, Llull University, Spain

Computational Approaches to Antibody Discovery and Optimization

Session Chair:
Cédric R. Weber, Ph.D., Director of Data Science and Bioinformatics, Alloy Therapeutics, Inc., Switzerland

Co-Stimulatory Antibodies and Combination Approaches in Oncology

Session Chair:
Katherine Harris, Ph.D., Chief Development Officer, Rondo Therapeutics

Antibody Theranostics: New Horizons

Session Chair:
Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom

Emerging Modalities: ADCs, Degraders and Beyond

Session Chair:
James Hunt, Director, R&D Biologics Engineering, AstraZeneca